Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
Abstract Background The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in patients with weight regain after bariatric surgery remains unclear. The objective of this study was to determine the efficacy and safety of 12 months of GLP1-RA treatment in a real-world patient population with...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12902-025-01913-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726737925013504 |
|---|---|
| author | Anders Boisen Jensen Ursina Machado Frida Renström Stefan Aczél Patrick Folie Magdalena Biraima-Steinemann Stefan Bilz |
| author_facet | Anders Boisen Jensen Ursina Machado Frida Renström Stefan Aczél Patrick Folie Magdalena Biraima-Steinemann Stefan Bilz |
| author_sort | Anders Boisen Jensen |
| collection | DOAJ |
| description | Abstract Background The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in patients with weight regain after bariatric surgery remains unclear. The objective of this study was to determine the efficacy and safety of 12 months of GLP1-RA treatment in a real-world patient population with weight regain after bariatric surgery. Methods A single-centre retrospective observational study. Patients with post-bariatric weight regain subsequently treated with GLP1-RA were identified, and the effect on weight after 12 months of treatment was determined. Data are presented as medians (interquartile ranges) or frequencies (%), and Wilcoxon signed-rank tests and Mann-Whitney U tests were used for paired and nonpaired group comparisons, respectively. Results Forty patients (80% female) were included in the analysis. Liraglutide (3.0 mg, daily subcutaneous injection, n = 22) or semaglutide (1.0 mg, weekly subcutaneous injection, n = 18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%. After 12 months of GLP1-RA treatment, a total body weight, BMI, and percentage excess body weight reduction of 10.5 (6.1, 14.7) kg, 3.7 (2.5, 5.3) kg/m2, and 41.7 (22.1, 70.5)% were observed, corresponding to a loss of 99.3 (61.0, 135.4)% of the weight regained (P-value < 0.0001). The observed reduction in BMI was significantly lower with liraglutide than with semaglutide, 3.1 (2.0, 4.7) vs. 4.7 (3.7, 6.0) kg/m2 (P-value = 0.04). Adverse events were reported in 13 (32.5%) patients, all of which were mild and transient. Conclusion GLP1-RA therapy with liraglutide or semaglutide for 12 months is efficacious and safe for the treatment of weight regain following bariatric surgery. Clinical trial number Not applicable. |
| format | Article |
| id | doaj-art-1aa42d66a0b74aafa629e4793119e16c |
| institution | DOAJ |
| issn | 1472-6823 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj-art-1aa42d66a0b74aafa629e4793119e16c2025-08-20T03:10:06ZengBMCBMC Endocrine Disorders1472-68232025-04-012511810.1186/s12902-025-01913-4Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational studyAnders Boisen Jensen0Ursina Machado1Frida Renström2Stefan Aczél3Patrick Folie4Magdalena Biraima-Steinemann5Stefan Bilz6Division of Endocrinology and Diabetes, Department of Internal Medicine, Cantonal Hospital of St. GallenDivision of Endocrinology and Diabetes, Department of Internal Medicine, Cantonal Hospital of St. GallenDivision of Endocrinology and Diabetes, Department of Internal Medicine, Cantonal Hospital of St. GallenDivision of Endocrinology and Diabetes, Department of Internal Medicine, Cantonal Hospital of St. GallenDivision of Surgery, Cantonal Hospital of St. GallenDivision of Surgery, Cantonal Hospital of St. GallenDivision of Endocrinology and Diabetes, Department of Internal Medicine, Cantonal Hospital of St. GallenAbstract Background The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in patients with weight regain after bariatric surgery remains unclear. The objective of this study was to determine the efficacy and safety of 12 months of GLP1-RA treatment in a real-world patient population with weight regain after bariatric surgery. Methods A single-centre retrospective observational study. Patients with post-bariatric weight regain subsequently treated with GLP1-RA were identified, and the effect on weight after 12 months of treatment was determined. Data are presented as medians (interquartile ranges) or frequencies (%), and Wilcoxon signed-rank tests and Mann-Whitney U tests were used for paired and nonpaired group comparisons, respectively. Results Forty patients (80% female) were included in the analysis. Liraglutide (3.0 mg, daily subcutaneous injection, n = 22) or semaglutide (1.0 mg, weekly subcutaneous injection, n = 18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%. After 12 months of GLP1-RA treatment, a total body weight, BMI, and percentage excess body weight reduction of 10.5 (6.1, 14.7) kg, 3.7 (2.5, 5.3) kg/m2, and 41.7 (22.1, 70.5)% were observed, corresponding to a loss of 99.3 (61.0, 135.4)% of the weight regained (P-value < 0.0001). The observed reduction in BMI was significantly lower with liraglutide than with semaglutide, 3.1 (2.0, 4.7) vs. 4.7 (3.7, 6.0) kg/m2 (P-value = 0.04). Adverse events were reported in 13 (32.5%) patients, all of which were mild and transient. Conclusion GLP1-RA therapy with liraglutide or semaglutide for 12 months is efficacious and safe for the treatment of weight regain following bariatric surgery. Clinical trial number Not applicable.https://doi.org/10.1186/s12902-025-01913-4Bariatric surgeryGLP-1 receptor agonistLiraglutideSemaglutideWeight regain |
| spellingShingle | Anders Boisen Jensen Ursina Machado Frida Renström Stefan Aczél Patrick Folie Magdalena Biraima-Steinemann Stefan Bilz Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study BMC Endocrine Disorders Bariatric surgery GLP-1 receptor agonist Liraglutide Semaglutide Weight regain |
| title | Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study |
| title_full | Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study |
| title_fullStr | Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study |
| title_full_unstemmed | Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study |
| title_short | Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study |
| title_sort | efficacy of 12 months therapy with glucagon like peptide 1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery a real world retrospective observational study |
| topic | Bariatric surgery GLP-1 receptor agonist Liraglutide Semaglutide Weight regain |
| url | https://doi.org/10.1186/s12902-025-01913-4 |
| work_keys_str_mv | AT andersboisenjensen efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy AT ursinamachado efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy AT fridarenstrom efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy AT stefanaczel efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy AT patrickfolie efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy AT magdalenabiraimasteinemann efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy AT stefanbilz efficacyof12monthstherapywithglucagonlikepeptide1receptoragonistsliraglutideandsemaglutideonweightregainafterbariatricsurgeryarealworldretrospectiveobservationalstudy |